Valuation Trading Multiples & Precedent Transactions: Biopharma Protein Therapeutics Companies
Valuation benchmarks for Biopharma Protein Therapeutics Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Biopharma Protein Therapeutics Companies Market Context & Valuation Drivers
Companies in this public trading comparables group are biopharmaceutical manufacturers developing and commercializing protein-based therapeutics, including monoclonal antibodies, recombinant proteins, and plasma-derived drugs, alongside adjacent biologics such as vaccines and cell therapies. They share R&D-driven pipelines, GMP biologics production, and hospital-focused distribution. Grouping them provides valuation benchmarks for biologics-centric revenue models, regulatory risk profiles, manufacturing scale, and margins tied to complex protein therapeutics.
Typical capabilities span discovery and clinical development of monoclonal antibodies, recombinant therapeutic proteins, and cytokines; plasma collection and fractionation to produce human albumin and immunoglobulins; large-scale fill-finish and cold-chain distribution; vaccine development and manufacturing; cell therapy platforms; aesthetic biomaterials such as sodium hyaluronate and collagen; and R&D services or out-licensing that monetize pipelines via milestones and royalties.
Primary customers include hospitals and clinics, specialty pharmacies and distributors, and public health agencies procuring vaccines; aesthetic medicine providers buy biomaterials. Key valuation metrics include late-stage pipeline depth, approval cadence, revenue growth from new launches, biologics gross margins and manufacturing yield, capacity utilization, and sustainability of demand via reimbursement and tenders. Analysts also assess geographic exposure and proprietary versus partnered product mix.
2. Valuation Analysis: Public Trading Comps & Multiples for Biopharma Protein Therapeutics Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Biopharma Protein Therapeutics Companies sector
Comparable group 1: Biopharma Protein Therapeutics Companies
Neuren Pharma
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biopharmaceutical therapies targeting neurodevelopmental disorders with a focus on developing drugs for conditions including Rett syndrome, Fragile X syndrome, and other severe neurological disorders emerging in early childhood.
- Key Products:
- DAYBUE (trofinetide): FDA-approved treatment for Rett syndrome in adults and children over two years old
- NNZ-2591: Drug in development for Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome, demonstrating efficacy in clinical trials.
Sichuan Biokin
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of pharmaceutical and biopharmaceutical solutions focusing on the research, development, manufacturing, and commercialization of innovative and generic drugs targeting cancer and other complex diseases
- Key Products:
- Chemical Drugs: Development and manufacturing of innovative chemical drugs for various therapeutic areas
- Biologics: Production of biologic treatments targeting cancer and complex diseases
- Anesthesia Products: Comprehensive portfolio for anesthesia and critical care applications
- Pediatric Medicines: Specialized drugs focusing on pediatric needs and treatment
- Antibody Drug Conjugates: Innovative oncology solutions utilizing antibody-drug conjugate technology